Achillion down after discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $0.45 (19%) to $1.95 on Tuesday after it said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound.

The decision is a delay for Achillion as it attempts to offer an alternative to Soliris eculizumab from Alexion Inc. (NASDAQ:ALXN)...